Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs, escitalopram and spironolactone. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat major depressive disorder and generalized anxiety disorder by increasing serotonin levels in the brain[3][4]. Spironolactone is a potassium-sparing diuretic and aldosterone antagonist used mainly for hypertension, heart failure, edema, and off-label for acne; it works by blocking aldosterone receptors in the kidneys to promote sodium excretion while retaining potassium[2][6]. There is no evidence of an approved fixed-dose combination product containing both agents; their co-administration may occur off-label but requires careful monitoring due to potential drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + spironolactone.